The US Government is set to purchase additional 180 million rapid Covid-19 tests in a bid to ensure the availability of test kits across the country. The move will involve an investment of around $1bn, Reuters reported. This investment is in addition to the $2bn commitment made by the government last month to procure test kits. In the US, the production of Covid-19 tests is expected to touch around 200 million per month by December.
SkyWater Technology and NanoDx have entered into a technology transfer collaboration to produce nanoscale sensors that can enhance and expand rapid testing for several indications, including Covid-19. The partnership will enable NanoDx to scale the product and advance with the plan to seek an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a two-minute, point-of-care Covid-19 test. The NanoDx System is designed to identify and quantify biomarkers from a small fluid specimen in less than two minutes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Todos Medical and its joint venture (JV) partner NLC Pharma have reported positive data from a clinical study that evaluated 3CL protease biomarker assay TolloTest. The trial assessed the sensitivity of the assay compared with PCR in hospitalised Covid-19 patients, other hospitalised patients and individuals exposed to confirmed Covid-19 subjects. The data indicates 100% sensitivity in identifying fully vaccinated asymptomatic Covid-19 patients, after one to three days of exposure.
